Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuraxis (NRXS) Research & Development (2022 - 2025)

Neuraxis (NRXS) has disclosed Research & Development for 4 consecutive years, with -$338053.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 178.14% to -$338053.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$330187.0 through Dec 2025, down 176.15% year-over-year, with the annual reading at $9380.0 for FY2025, 97.84% down from the prior year.
  • Research & Development hit -$338053.0 in Q4 2025 for Neuraxis, down from $1515.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $432636.0 in Q4 2024 to a low of -$338053.0 in Q4 2025.
  • Historically, Research & Development has averaged $34919.5 across 4 years, with a median of $13665.0 in 2022.
  • Biggest five-year swings in Research & Development: soared 19579.33% in 2024 and later tumbled 178.14% in 2025.
  • Year by year, Research & Development stood at $81371.0 in 2022, then crashed by 102.73% to -$2221.0 in 2023, then skyrocketed by 19579.33% to $432636.0 in 2024, then crashed by 178.14% to -$338053.0 in 2025.
  • Business Quant data shows Research & Development for NRXS at -$338053.0 in Q4 2025, $1515.0 in Q3 2025, and $4394.0 in Q2 2025.